Skip to main content

Gyros Partners with EMD Millipore to Develop and Commercialize Immunoassays on Gyrolab Platform

Premium

Gyros this week announced a partnership with EMD Millipore to develop, manufacture, and commercialize immunoassay kits for the Gyrolab platform.

The new kits will take advantage of the capabilities of Gyros' microfluidic technology, which, according to the company, requires smaller sample and reagent volumes and offers increased dynamic range and reduced cross-talk and matrix interference compared to traditional ELISAs.

“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” Jehangir Mistry, general manager, Multiplex & Immunoassays at EMD Millipore, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.